EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Ustekinumab is safe and effective in pediatric patients with Crohn's disease

Elana B Mitchel iD, Michael T Dolinger, Brad Constant, Zi Wang, Daniela Guisado, Michael Gao, Steven Fusillo, Robert N Baldassano, Judith Kelsen, Marla Dubinsky, Jing Huang, Lindsey Albenberg

Journal of Pediatric Gastroenterology and Nutrition · 2025

DOI: 10.1002/jpn3.12452 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2025. Verfasst von Elana B Mitchel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Ustekinumab, Crohn Disease. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, None.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Real‐world data on ustekinumab for the treatment of pediatric Crohn's disease (CD) are limited. This study sought to evaluate the effectiveness, long‐term durability, and safety of ustekinumab in the treatment of children with CD.

Methods

A retrospective longitudinal cohort study of children with CD treated with ustekinumab from two large centers between 2015 and 2020 was performed. The primary outcome was frequency of steroid‐free clinical remission at 1 year. Secondary outcomes included time to steroid‐free clinical remission, frequency of clinical and biochemical remission, drug escalation and discontinuation, serum level data, and adverse events. Standard descriptive and comparative statistics were performed. Logistic regression was used to identify factors associated with steroid‐free remission at 1 year. Kaplan–Meier curves were used to visualize time‐to‐event relationships for outcomes.

Results

A total of 101 patients were included. Median follow‐up time on ustekinumab was 16.6 months (interquartile range [IQR]: 8.71–31.2) with drug failure in 28% at 1 year. Fifty‐nine patients were in steroid‐free clinical remission at 1 year. Higher baseline disease activity (odds ratio [OR]: 0.91 (95% confidence interval [CI]: 0.84–0.97), p = 0.01) and stricturing/penetrating disease phenotype (OR: 0.14 (95% CI: 0.03–0.65), p = 0.02) were associated with decreased likelihood of steroid‐free clinical remission at 1‐year. Ustekinumab drug escalation occurred in 70% of patients, and after escalation, 50 (70%) achieved clinical remission, and 49 (69%) achieved steroid‐free remission at the last follow‐up. Adverse events were rare and did not require therapy discontinuation.

Conclusions

Ustekinumab is effective and safe in the treatment of children with CD. Escalation of therapy occurs frequently but results in sustained durability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UstekinumabCrohn DiseaseHumansMaleFemaleRetrospective StudiesChildAdolescentLongitudinal StudiesTreatment OutcomeRemission Induction

Stichwörter der Autor:innen

inflammatory bowel diseasesteroid‐free clinical remission

Substanzen

Ustekinumab

Autor:innen und Institutionen

  • Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
  • Susan and Leonard Feinstein Inflammatory Bowel Disease Center at Mount Sinai, New York, New York, USA.
  • Icahn School of Medicine at Mount Sinai, New York, New York, USA.

ORCID-Profile: Elana B Mitchel

Förderung

  • NICHD NIH HHS
  • None

Zitieren

APA

Mitchel, E. B., Dolinger, M. T., Constant, B., Wang, Z., Guisado, D., Gao, M., Fusillo, S., Baldassano, R. N., Kelsen, J., Dubinsky, M., Huang, J., & Albenberg, L. (2025). Ustekinumab is safe and effective in pediatric patients with Crohn's disease. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.12452

Vancouver

Mitchel EB, Dolinger MT, Constant B, Wang Z, Guisado D, Gao M, et al. Ustekinumab is safe and effective in pediatric patients with Crohn's disease. Journal of Pediatric Gastroenterology and Nutrition. 2025. doi:10.1002/jpn3.12452

BibTeX
@article{Mitchel2025,
  author = {Mitchel, Elana B and Dolinger, Michael T and Constant, Brad and Wang, Zi and Guisado, Daniela and Gao, Michael and Fusillo, Steven and Baldassano, Robert N and Kelsen, Judith and Dubinsky, Marla and Huang, Jing and Albenberg, Lindsey},
  title = {Ustekinumab is safe and effective in pediatric patients with Crohn's disease},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2025},
  doi = {10.1002/jpn3.12452}
}
Kostenlos starten →